Trial Profile

A Randomized Phase II Study of OGX-011 [custirsen sodium] in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Hormone Refractory Prostate Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Sep 2010 Results have been published in the Journal of Clinical Oncology (Sep 20, 2010: 4247-4254), according to an OncoGenex Pharmaceuticals media release.
07 Oct 2009 US FDA granted fast track designation for custirsen [OGX-011] in combination with first-line chemotherapy, based on the results of this trial.
20 Sep 2009 Results presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology (ECCO/ESMO 2009).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com